Literature DB >> 12090755

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.

Cristina Gasparetto1, Maura Gasparetto, Michael Morse, Barbara Rooney, James J Vredenburgh, Gwynn D Long, David A Rizzieri, Jennifer Loftis, Nelson J Chao, Clay Smith.   

Abstract

Treatment with myeloablative chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation followed by vaccination with autologous dendritic cells (DCs) treated with tumor antigens is a promising therapeutic strategy for several types of cancer. Obtaining sufficient numbers of both PBSCs and DCs is central to this approach. Previously, it has been shown that administration of Flt-3-Ligand (FL) combined with either G-CSF or GM-CSF mobilizes large numbers of PBSCs in patients with cancer. In the current study, we sought to determine whether these same cytokines could simultaneously mobilize DCs into the PBSC leukapheresis collection. DCs were analysed in PBSC leukapheresis samples obtained from five patients with high-risk breast cancer who received G-CSF alone as priming prior to leukapheresis, four patients who received FL+G-CSF and five patients who received FL+GM-CSF. DCs were defined as cells with a lin(dim/-) HLA-DR+ CD11c+ phenotype. The proportions of DCs in the FL+G-CSF and FL+GM-CSF samples were significantly higher than in pre-mobilization peripheral blood and G-CSF leukapheresis samples. The mean yield of DCs/kg in the FL+GM-CSF samples was also significantly higher than the mean yield of DCs in the G-CSF samples. The FL+G-CSF and FL+GM-CSF mobilized DCs were immature by morphologic and phenotypic criteria but stimulated allogeneic T-cells at levels similar to DCs generated in culture from PBMCs. Overnight culture?of the immature DCs obtained from patients receiving either FL+G-CSF or FL+GM-CSF in TNF-alpha?resulted in the generation of mature DCs. In summary, administration of FL in combination with GM-CSF and G-CSF to patients with breast cancer can mobilize large numbers of immature DCs into PBSC leukapheresis collections. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090755     DOI: 10.1006/cyto.2002.1009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo.

Authors:  Robert K Strother; Derek B Danahy; Dmitri I Kotov; Tamara A Kucaba; Zeb R Zacharias; Thomas S Griffith; Kevin L Legge; Vladimir P Badovinac
Journal:  J Immunol       Date:  2016-10-26       Impact factor: 5.422

2.  Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

Authors:  N Anandasabapathy; G Breton; A Hurley; M Caskey; C Trumpfheller; P Sarma; J Pring; M Pack; N Buckley; I Matei; D Lyden; J Green; T Hawthorne; H C Marsh; M Yellin; T Davis; T Keler; S J Schlesinger
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

3.  FMS-like tyrosine kinase 3 ligand treatment of mice aggravates acute lung injury in response to Streptococcus pneumoniae: role of pneumolysin.

Authors:  Christina Brumshagen; Regina Maus; Andrea Bischof; Bianca Ueberberg; Jennifer Bohling; John J Osterholzer; Abiodun D Ogunniyi; James C Paton; Tobias Welte; Ulrich A Maus
Journal:  Infect Immun       Date:  2012-09-24       Impact factor: 3.441

4.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03

5.  CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice.

Authors:  Merriline Satyamitra; Lynnette Cary; Dylan Dunn; Gregory P Holmes-Hampton; Lawrence J Thomas; Sanchita P Ghosh
Journal:  Sci Rep       Date:  2020-02-04       Impact factor: 4.379

Review 6.  The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines.

Authors:  Benjamin Gordon; Vijayakrishna K Gadi
Journal:  Vaccines (Basel)       Date:  2020-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.